Financials EuroEyes International Eye Clinic Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
5.55 ^HKD	+0.91%		-0.54%	+6.53%

May. 02	EuroEyes International Eye Clinic Limited commences an Equity Buyback Plan for 33,324,000 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.	CI
Apr. 26	EuroEyes International to Buy Back Up to 3% Shares	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	2,759	2,878	2,693	1,829	1,848	1,848	-
Enterprise Value (EV) ¹	2,759	2,878	2,693	1,829	1,736	1,848	1,848
P/E ratio	-652 x	50.1 x	20.2 x	20.4 x	13.2 x	9.25 x	-
Yield	-	-	1.21%	1.14%	1.98%	2.52%	-
Capitalization / Revenue	6.71 x	6.07 x	4.26 x	3 x	2.43 x	2.15 x	1.86 x
EV / Revenue	6.71 x	6.07 x	4.26 x	3 x	2.43 x	2.15 x	1.86 x
EV / EBITDA	21.3 x	15.2 x	10.1 x	8.57 x	6.18 x	5.63 x	4.58 x
EV / FCF	86.1 x	71.7 x	-	23.8 x	16.1 x	18 x	13.1 x
FCF Yield	1.16%	1.39%	-	4.21%	6.2%	5.56%	7.64%
Price to Book	2.77 x	3.02 x	2.67 x	1.8 x	1.6 x	1.41 x	-
Nbr of stocks (in thousands)	329,234	329,234	329,234	333,240	333,040	333,040	-
Reference price ²	8.380	8.740	8.180	5.490	5.550	5.550	5.550
Announcement Date	3/25/20	3/16/21	3/23/22	3/28/23	3/28/24	-	-

¹HKD in Million²HKD

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	368.7	411.4	473.8	632.9	610.3	714.3	858.4	994.2
EBITDA ¹	-	129.7	189.2	265.9	213.5	280.9	328	403.3
EBIT ¹	-	29.13	107.6	189.8	132.8	193.5	248.8	272.6
Operating Margin	-	7.08%	22.7%	29.99%	21.76%	27.09%	28.99%	27.42%
Earnings before Tax (EBT) ¹	-	20.41	98.65	195.7	129	190.6	247	271.9
Net income ¹	-	-3.293	65.58	133.6	89.47	131.2	174.8	207.6
Net margin	-	-0.8%	13.84%	21.1%	14.66%	18.37%	20.36%	20.89%
EPS ²	-	-0.0128	0.1746	0.4058	0.2693	0.3950	0.6000	-
Free Cash Flow ¹	-	32.03	40.12	-	76.95	114.6	102.7	141.2
FCF margin	-	7.79%	8.47%	-	12.61%	15.42%	11.96%	14.2%
FCF Conversion (EBITDA)	-	24.7%	21.2%	-	36.04%	37.39%	31.31%	35.01%
FCF Conversion (Net income)	-	-	61.17%	-	86.01%	72.37%	58.77%	68%
Dividend per Share ²	-	-	-	0.0993	0.0627	0.1100	0.1400	-
Announcement Date	9/29/19	3/25/20	3/16/21	3/23/22	3/28/23	3/28/24	-	-

¹HKD in Million²HKD

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	32	40.1	-	77	115	103	141
ROE (net income / shareholders' equity)	-	9.78%	8.19%	14.1%	8.86%	17.3%	17%	14.7%
ROA (Net income/ Total Assets)	-	5.55%	5.66%	9.96%	6.15%	9.9%	10.2%	9.6%
Assets ¹	-	-59.33	1,159	1,342	1,455	1,599	1,722	2,163
Book Value Per Share ²	-	3.030	2.900	3.060	3.040	3.460	3.950	-
Cash Flow per Share ²	-	-	0.2100	0.8300	0.6300	0.2200	0.7200	-
Capex ¹	-	27.9	38.3	44	56.3	98.3	75.8	68.9
Capex / Sales	-	6.79%	8.09%	6.95%	9.23%	13.22%	8.83%	6.93%
Announcement Date	9/29/19	3/25/20	3/16/21	3/23/22	3/28/23	3/28/24	-	-

¹HKD in Million²HKD

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.55 HKD

Average target price

7.26 HKD

Spread / Average Target

+30.81%

	1st Jan change	Capi.
EUROEYES INTERNATIONAL EYE CLINIC LIMITED	+6.53%	237M
HUAXIA EYE HOSPITAL GROUP CO.,LTD.	-18.17%	3.03B
TOPCHOICE MEDICAL CO., INC.	-15.24%	2.87B
AIRSCULPT TECHNOLOGIES, INC.	-36.72%	273M
MEDSCI HEALTHCARE HOLDINGS LIMITED	-46.54%	175M
AESTHETIC CONNECT	-33.52%	113M